Epigenomics Septin9 Biomarker detects Colon Cancer equally in both sides of the Colon
In a blinded case control study of a total of 184 study participants, plasma from 92 CRC cases (56 left-, 36 right-sided cases) was analyzed and methylated Septin9 was detected in a total of 88 cancer cases, representing 96% sensitivity for overall CRC detection at a specificity of 85%. The control arm consisted of 92 samples of individuals with no evidence of disease as verified by colonoscopy. Sensitivity for detection of left- and right-sided cases was 96% and 94% respectively, thus showing no significant difference between cancer detection in either side of the colon.
In a subset of 39 subjects that received a fecal occult blood test (FOBT, Hemoccult II stool test) in addition to a Septin9 test, the sensitivities for FOBT for the detection of 12 left- sided cases was 83% and 50% for the 10 right-sided cases in this study. Overall, sensitivity for FOBT was 68% and specificity was 71%.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.